Language selection

Search

Patent 2305062 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2305062
(54) English Title: COMPOSITIONS FOR AND METHOD OF TREATMENT FOR PSORIASIS
(54) French Title: COMPOSES ET METHODES DE TRAITEMENT DU PSORIASIS
Status: Deemed Abandoned and Beyond the Period of Reinstatement - Pending Response to Notice of Disregarded Communication
Bibliographic Data
(51) International Patent Classification (IPC):
  • A61K 36/61 (2006.01)
  • A61K 09/06 (2006.01)
  • A61K 09/12 (2006.01)
  • A61K 35/04 (2006.01)
  • A61K 36/53 (2006.01)
  • A61K 45/08 (2006.01)
  • A61P 17/06 (2006.01)
(72) Inventors :
  • DE OLIVEIRA, MARIANA (Canada)
(73) Owners :
  • MARIANA DE OLIVEIRA
(71) Applicants :
  • MARIANA DE OLIVEIRA (Canada)
(74) Agent: EUGENE J. A. GIERCZAKGIERCZAK, EUGENE J. A.
(74) Associate agent:
(45) Issued:
(22) Filed Date: 2000-04-12
(41) Open to Public Inspection: 2001-10-12
Examination requested: 2002-06-28
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): No

(30) Application Priority Data: None

Abstracts

English Abstract


Improved compositions for treating psoriasis, including a body wash
composition, spray composition and cream composition and the use of these
novel
compositions in a system or method of treating psoriasis.


Claims

Note: Claims are shown in the official language in which they were submitted.


-11-
CLAIMS
I CLAIM:
1. A composition for use in a psoriasis treatment comprising active agents and
a
carrier mixture, wherein said active agents are coal tar and a herbal extract
in a
therapeutic effective dose, wherein said herbal extract is selected from a
group
consisting of mallow extract, rosemary extract and eucalyptus extract and said
active agent mixes with said carrier mixture for administration of said
composition.
2. A composition for treating psoriasis consisting of the following
ingredients in
the following percentage range by weight:
(a) Water in the range of 40.19 - 49.12
(b) Sodium laureth sulphate in the range of 31.5 - 38.5
(c) Cocamide DEA in the range of 4.5 - 5.5
(d) Cocamidopropyl betaine in the range of 0.9 - 1.1
(e) Proylene glycol in the range of 0.27 - 0.33
(f) Citric acid in the range of 0.27 - 0.33
(g) Coal tar topical solution in the range of 5.4 - 6.6
(h) Sodium chloride in the range of 1.8 - 2.2
(i) Sodium layroyl sarcosinate in the range of 1.8 - 2.2
(j) Wheat germ oil in the range of 0.45 - 0.55
(k) Proteins (blends) in the range of 0.18 - 0.22
(l) Methylchloroisothiazolinone in the range of 0.045 - 0.045
(m) Mallow extract in the range of 0.9 - 1.1
(n) Rosemary oil in the range of 0.45 - .55

-12-
(o) Eucalyptus oil in the range of 0.45 - .55
(p) Carbomer in the range of 0.9 - 1.1
3. A composition for treating psoriasis consisting of the following
ingredients in
the following percentage range by weight:
(a) Water in the range of 21.573 - 26.367
(b) Alcohol in the range of 63 - 77
(c) Sodium Iodide in the range of 2.7 - 3.3
(d) Potassium iodide in the range of 1.35 - 1.65
(e) Sodium thiosulphate in the range of 0.027 - 0.033
(f) Mallow extract in the range of 0.9 - 1.1
(g) Rosemary oil in the range of 0.225 - 0.27
(h) Eucalyptus oil in the range of 0.225 - 0.27
4. A composition for treating psoriasis consisting of the following
ingredients in
the following percentage range by weight:
(a) Water in the range of 47.0205 - 57.4695
(b) Propylene glycol in the range of 3.6 - 4.4
(c) Mineral oil in the range of 2.7 - 3.3
(d) Cetyl alcohol in the range of 3.6 - 4.4
(e) Stearic acid in the range of 3.6 - 4.4
(f) Glycerol monostearate in the range of 2.7 - 3.3
(g) F D and C Yellow #5 solution in the range of 0.045 - 0.055
(h) D and C red #33 solution in the range of 0.0045 - 0.055
(i) Chamomile extract in the range of 0.9 - 1.1

-13-
(j) Carbomer in the range of 3.6 - 4.4
(k) Methyl paraben in the range of 0.225 - 0.275
(l) Propyl paraben in the range of 0.09 - 0.11
(m) Triethanolamine in the range of 0.54 - 0.66
(n) Milk amino acids in the range of 2.25 - 2.75
(o) Tea tree solution in the range of 2.7 - 3.3
(p) Mallow extract in the range of 0.9 - 1.1
(q) Coal tar topical solution in the range of 5.175 - 6.325
(r) Dimethicone in the range of 0.45 - 0.55
(s) Glycerine in the range of 2.7 - 3.3
(t) Petrolatum in the range of 0.9 - 1.1
(u) Cetearyl alcohol in the range of 2.25 - 2.75
(v) Ceteareth 20 in the range of 2.25 - 2.75
(w) Polysorbate 20 in the range of 1.8 - 2.2
5. A pharmaceutical composition for use in the treatment of psoriasis
comprising
an anti-psoriatic agent selected from the group consisting of coal tar
solution
and herbal extracts, said anti-psoriatic agent being present in an effective
anti-
psoriatic percentage mixed with a carrier mixture for topical administration
to
a human.
6. A pharmaceutical composition for use in the treatment of psoriasis as
claimed
in claim 5 said composition being at least five percent coal tar and at least
one
percent mallow extract.

-14-
7. A system for use in a psoriasis treatment comprising a body wash
composition, a spray composition and a cream composition, wherein said body
wash composition, said spray composition and said cream composition further
comprises an active agent and carrier mixture, wherein said active agent is
coal tar and herbal extracts in a therapeutic effective dose, and said active
agent mixes with said carrier mixture for administration of said body wash
composition, said spray composition and said cream composition.
8. A system for use in a psoriasis treatment as claimed in claim 7 wherein
said
body wash composition consisting of the following ingredients in the
following range of proportions based on weight:
(a) Water in the range of 40.19 - 49.12
(b) Sodium laureth sulphate in the range of 31.5 - 38.5
(c) Cocamide DEA in the range of 4.5 - 5.5
(d) Cocamidopropyl betaine in the range of 0.9 - 1.1
(e) Proylene glycol in the range of 0.27 - 0.33
(f) Citric acid in the range of 0.27 - 0.33
(g) Coal tar topical solution in the range of 5.4 - 6.6
(h) Sodium chloride in the range of 1.8 - 2.2
(i) Sodium layroyl sarcosinate in the range of 1.8 - 2.2
(j) Wheat germ oil in the range of 0.45 - 0.55
(k) Proteins (blends) in the range of 0.18 - 0.22
(l) Methylchloroisothiazolinone in the range of 0.045 - 0.055
(m) Mallow extract in the range of 0.9 - 1.1
(n) Rosemary oil in the range of 0.45 - 5.5
(o) Eucalyptus oil in the range of 0.45 - 5.5
(p) Carbomer in the range of 0.9 - 1.1

-15-
9. A system for use in a psoriasis treatment as claimed in claim 7 wherein
said
spraying solution consisting of the following ingredients in the following
range of proportions based on weight:
(a) Water in the range of 21.573 - 26.367
(b) Alcohol in the range of 63 - 77
(c) Sodium Iodide in the range of 2.7 - 3.3
(d) Potassium iodide in the range of 1.35 - 1.65
(e) Sodium thiosulphate in the range of 0.027 - 0.033
(f) Mallow extract in the range of 0.9 - 1.1
(g) Rosemary oil in the range of 0.225 - 0.27
(h) Eucalyptus oil in the range of 0.225 - 0.27
10. A system for use in a psoriasis treatment as claimed in claim 7 wherein
said
cream composition consisting of the following ingredients in the following
range of proportions:
(a) Water in the range of 47.0205 - 27.4695
(b) Propylene glycol in the range of 3.6 - 4.4
(c) Mineral oil in the range of 2.7 - 3.3
(d) Cetyl alcohol in the range of 3.6 - 4.4
(e) Stearic acid in the range of 3.6 - 4.4
(f) Glycerol monostearate in the range of 2.7 - 3.3
(g) Coal tar topical solution in the range of 5.175 - 6.325
(h) Chamomile extract in the range of 0.9 - 1.1
(i) Methyl paraben in the range of 0.225 - 0.275
(j) Propyl paraben in the range of 0.09 - 0.11
(k) Triethanolamine in the range of 0.54 - 0.66

-16-
(l) Milk amino acids in the range of 2.25 - 2.75
(m) Mallow extract in the range of 0.9 - 1.1
(n) Tea tree solution in the range of 2.7 - 3.3
(o) Dimethicone in the range of 0.45 - 0.55
(p) Carbomer in the range of 3.6 - 4.4
(q) Glycerine in the range of 2.7 - 3.3
(r) Petrolatum in the range of 0.9 - 1.1
(s) Cetearyl alcohol in the range of 2.25 - 2.75
(t) Ceteareth 20 in the range of 2.25 - 2.75
(u) Polysorbate 20 in the range of 1.8 - 2.2
(v) F D and C Yellow #5 solution in the range of 0.045 - 0.055
(w) D and C red #33 solution in the range of 0.0045 - 0.055
11. A method of treating psoriasis comprising topically administering to a
human
having psoriasis an effective amount of coal tar and herbal extract, said coal
tar and herbal extract being present in a topically acceptable pharmaceutical
body wash composition.
12. A method as claimed in claim 11 wherein said topically acceptable
pharmaceutical bathing composition consisting of the following ingredients in
the following range of proportions:
(a) Water in the range of 40.19 - 49.12
(b) Sodium laureth sulphate in the range of 31.5 - 38.5
(c) Cocamide DEA in the range of 4.5 - 5.5
(d) Cocamidopropyl betaine in the range of 0.9 - 1.1
(e) Proylene glycol in the range of 0.27 - 0.33

-17-
(f) Citric acid in the range of 0.27 - 0.33
(g) Coal tar topical solution in the range of 5.4 - 6.6
(h) Sodium chloride in the range of 1.8 - 2.2
(i) Sodium layroyl sarcosinate in the range of 1.8 - 2.2
(j) Wheat germ oil in the range of 0.45 - 0.55
(k) Proteins (blends) in the range of 0.18 - 0.22
(l) Methylchloroisothiazolinone in the range of 0.045 - 0.055
(m) Mallow extract in the range of 0.9 - 1.1
(n) Rosemary oil in the range of 0.45 - .55
(o) Eucalyptus oil in the range of 0.45 - .55
(p) Carbomer in the range of 0.9 - 1.1
13. A method of treating psoriasis comprising topically administering to a
human
having psoriasis an effective amount of coal tar and herbal extract, said coal
tar and herbal extract being present in a topically acceptable pharmaceutical
spray composition.
14. A method for use in a psoriasis treatment as claimed in claim 13 wherein
said topically acceptable pharmaceutical spraying composition consisting of
the following ingredients in the following range of proportions:
(a) Water in the range of 21.573 - 26.367
(b) Alcohol in the range of 63 - 77
(c) Sodium Iodide in the range of 2.7 - 3.3
(d) Potassium iodide in the range of 1.35 - 1.65
(e) Sodium thiosulphate in the range of 0.027 - 0.033
(f) Mallow extract in the range of 0.9 - 1.1

-18-
(g) Rosemary oil in the range of 0.225 - 0.27
(h) Eucalyptus oil in the range of 0.225 - 0.27
15. A method of treating psoriasis comprising topically administering to a
human
having psoriasis an effective amount of coal tar and herbal extract, said coal
tar and herbal extract being present in a topically acceptable pharmaceutical
cream composition.
16. A method of treating psoriasis as claimed in claim 15 wherein said
topically
acceptable pharmaceutical cream composition consisting of the following
ingredients in the following range of proportions:
(a) Water in the range of 47.0205 - 27.4695
(b) Propylene glycol in the range of 3.6 - 4.4
(c) Mineral oil in the range of 2.7 - 3.3
(d) Cetyl alcohol in the range of 3.6 - 4.4
(e) Stearic acid in the range of 3.6 - 4.4
(f) Glycerol monostearate in the range of 2.7 - 3.3
(g) Coal tar topical solution in the range of 5.175 - 6.325
(h) Chamomile extract in the range of 0.9 - 1.1
(i) Methyl paraben in the range of 0.225 - 0.275
(j) Propyl paraben in the range of 0.09 - 0.11
(k) Triethanolamine in the range of 0.54 - 0.66
(l) Milk amino acids in the range of 2.25 - 2.75
(m) Mallow extract in the range of 0.9 - 1.1
(n) Tea tree solution in the range of 2.7 - 3.3
(o) Dimethicone in the range of 0.45 - 0.55

-19-
(p) Carbomer in the range of 3.6 - 4.4
(q) Glycerine in the range of 2.7 - 3.3
(r) Petrolatum in the range of 0.9 - 1.1
(s) Cetearyl alcohol in the range of 2.25 - 2.75
(t) Ceteareth 20 in the range of 2.25 - 2.75
(u) Polysorbate 20 in the range of 1.8 - 2.2
(v) F D and C Yellow #5 solution in the range of 0.045 - 0.055
(w) D and C red #33 solution in the range of 0.0045 - 0.055
17. A method for treating psoriasis comprising topically administering to a
human having psoriasis an effective amount of coal tar and herbal extract,
said coal tar and herbal extract being present in a topically acceptable
pharmaceutical body wash composition, spray composition and cream
composition.
18. A method as claimed in claim 17 wherein said body wash composition
consisting of the following ingredients in the following range of proportions:
(a) Water in the range of 40.19 - 49.12
(b) Sodium laureth sulphate in the range of 31.5 - 38.5
(c) Cocamide DEA in the range of 4.5 - 5.5
(d) Cocamidopropyl betaine in the range of 0.9 - 1.1
(e) Proylene glycol in the range of 0.27 - 0.33
(f) Citric acid in the range of 0.27 - 0.33
(g) Coal tar topical solution in the range of 5.4 - 6.6
(h) Sodium chloride in the range of 1.8 - 2.2
(i) Sodium layroyl sarcosinate in the range of 1.8 - 2.2

-20-
(j) Wheat germ oil in the range of 0.45 - 0.55
(k) Proteins (blends) in the range of 0.18 - 0.22
(l) Methylchloroisothiazolinone in the range of 0.045 - 0.055
(m) Mallow extract in the range of 0.9 - 1.1
(n) Rosemary oil in the range of 0.45 - .55
(o) Eucalyptus oil in the range of 0.45 - .55
(p) Carbomer in the range of 0.9 - 1.1
19. A system for use in a psoriasis treatment as claimed in claim 18 wherein
said
spray composition consisting of the following ingredients in the following
range of proportions:
(a) Water in the range of 21.573 - 26.367
(b) Alcohol in the range of 63 - 77
(c) Sodium Iodide in the range of 2.7 - 3.3
(d) Potassium iodide in the range of 1.35 - 1.65
(e) Sodium thiosulphate in the range of 0.027 - 0.033
(f) Mallow extract in the range of 0.9 - 1.1
(g) Rosemary oil in the range of 0.225 - 0.27
(h) Eucalyptus oil in the range of 0.225 - 0.27
20. A system for use in a psoriasis treatment as claimed in claim 19 wherein
said
cream composition consisting of the following ingredients in the following
range of proportions:
(a) Water in the range of 47.0205 - 27.4695
(b) Propylene glycol in the range of 3.6 - 4.4
(c) Mineral oil in the range of 2.7 - 3.3

-21-
(d) Cetyl alcohol in the range of 3.6 - 4.4
(e) Stearic acid in the range of 3.6 - 4.4
(f) Glycerol monostearate in the range of 2.7 - 3.3
(g) Coal tar topical solution in the range of 5.175 - 6.325
(h) Chamomile extract in the range of 0.9 - 1.1
(i) Methyl paraben in the range of 0.225 - 0.275
(j) Propyl paraben in the range of 0.09 - 0.11
(k) Triethanolamine in the range of 0.54 - 0.66
(l) Milk amino acids in the range of 2.25 - 2.75
(m) Mallow extract in the range of 0.9 - 1.1
(n) Tea tree solution in the range of 2.7 - 3.3
(o) Dimethicone in the range of 0.45 - 0.55
(p) Carbomer in the range of 3.6 - 4.4
(q) Glycerine in the range of 2.7 - 3.3
(r) Petrolatum in the range of 0.9 - 1.1
(s) Cetearyl alcohol in the range of 2.25 - 2.75
(t) Ceteareth 20 in the range of 2.25 - 2.75
(u) Polysorbate 20 in the range of 1.8 - 2.2
(v) F D and C Yellow #5 solution in the range of 0.045 - 0.055
(w) D and C red #33 solution in the range of 0.0045 - 0.055

Description

Note: Descriptions are shown in the official language in which they were submitted.


E
CA 02305062 2000-04-12
Compositions for and Method of Treatment for Psoriasis
Field of the Invention
This invention relates in general to a treatment for psoriasis and more
particularly to a medication for treating psoriasis having three different
formulations,
a system for using the medication, and a method of medical treatment.
1o Background of the Invention
Psoriasis is a skin disorder that includes the presence of small elevations of
the
skin that may be characterized as elevated red lesions, plaques or pustules on
the skin
which eventually result in silvery scales. These silvery scales and plaque are
the
result of accelerated epidermal proliferation and the metabolic activity and
proliferation of capillaries in the dermal region and the invasion of the
dermis and
epidermis by inflammatory cells. More specifically, the capillaries in the
dermal
region become tortuous and dilated as well as suffering an inflammatory
reaction
causing the skin to redden.
The exact mechanism which triggers the abnormal cell proliferation is not
known, though it is believed there may be biochemical stimuli and
environmental
factors. The severity and course of psoriasis can vary greatly depending on
the
individual, but in general this chronic skin condition recurs throughout the
life of the
individual with varying intervals of one month to many years.
Over the years a wide variety of methods of treatment for psoriasis, both
topical and systemic, which inhibit the cell division have been developed. In
general,
these methods have met with limited short term success and are not very well
understood. As the disease requires treating the individual intermittently
during their
lifetime, treatment risk increases with treatment length since common
medicaments
evidence cumulative long term side effects.

CA 02305062 2000-04-12
-2-
Historically, psoriasis has been treated topically with coal tar derivatives
as
well as salicylic acid with limited success. Corticosteroids and other similar
drugs
have been found effective for serious cases of psoriasis. Unfortunately many
of these
drugs produce serious side effects, and in some cases once the drugs are
discontinued,
the psoriasis recurs with marked exacerbation. Other forms of treatment
include folic
acid antagonists, ionizing radiation therapy, a variety of combinations of
ointments
and polyethylene films, sunlight and ultraviolet baths.
Prior art psoriasis medications and methods of medical treatment have been
1o devised to address the aforenoted problems. For example, United States
Patent No.
5,425,954 issued on June 20, 1995 to Thompson et al. and provides for a
composition
for topical application to the skin comprising a mixture of Panthenol (BS),
Cod Liver
Oil, Alpha Tocopherol Acetate, Arginine, Isoleucine, Leucine, Methionine,
Phenylalanine, Threonine, and Valine in admixture with a suitable Garner.
United States Patent No. 5,165,932 issued on November 24, 1992 to Horvath
and relates to therapeutical compositions on medical herb basis for the
treatment of
psoriasis and the preparation of the same. The medical herbs used in the
invention are
Album sativum/garlic/, Urtica dioicalcommon nettle/, Chelidonium
majus/milkweed/,
2o Veronica officinalis/veronical, Calendula officinalis/calendula or
marigold/, Achillea
herbalmillefolium/yarrow/ and Fumaria officinalis/fumitory, earth-gall.
United States Patent No. 4,981,681 issued on January 1, 1991 to Tosti and
relates to a method for treating psoriasis and more particularly it relates to
a method
of treating psoriasis by systematic and periodic application of several
selected
ingredients including the active ingredient Salicylic Acid.
United States Patent No. 5,886,038 issued on March 23, 1999 to Glenn et al.
and relates to a pharmaceutical composition for use in the treatment of
psoriasis,
3o having isopropyl myristate as its only active ingredient.

CA 02305062 2000-04-12
-3-
United States Patent No. 5,990,100 issued on November 23, 1999 to
Rosenbert et al. and this patent relates to pharmaceutical compositions and
methods
for use in the treatment of psoriasis, having isopropyl myristate as a first
active
ingredient and a different anti-psoriatic agent as a second active ingredient;
preferably
they are combined in the same pharmaceutical composition.
Thus a composition, system and method of treatment for psoriasis which
allows for the successful treatment by reducing the frequency of the
recurrence of the
psoriasis is desirable.
to
Summary of the Invention
An object of one aspect of the present invention is to provide improved
compositions or pharmaceutical compositions for use in the treatment of
psoriasis. A
further object of the invention is to provide an improved system for treatment
of
psoriasis or method of medical treatment using novel compositions.
In accordance with one aspect of the present invention there is provided a
composition for use in a psoriasis treatment comprising of an active agent
wherein the
2o active agent is coal tar and herbal extracts including mallow extract that
may be
mixed with a carrier mixture for topical administration.
In accordance with other aspects of the invention there are provided
compositions for treating psoriasis that include a body wash composition, a
spraying
composition and a cream composition. Conveniently the active agents may
include
coal tar a variety of herbal extracts, including and mallow extract.
In accordance with another aspect of the invention there is provided a system
for use in a psoriasis treatment that includes using a bathing composition, a
spraying
3o composition and a cream composition wherein the active agents include coal
tar
solution, herbal extracts including mallow extract in therapeutic effective
doses and a
carrier mixture for topical application.

CA 02305062 2000-04-12
-4-
In a final aspect of the present invention there is provided a method of
treating
psoriasis by topically administering to a human having psoriasis an effective
amount
of coal tar and herbal extracts including mallow extract, wherein the coal tar
and
herbal extract are present in a topically acceptable pharmaceutical bathing
composition, spraying composition and cream composition.
Detailed Description of the Preferred Embodiment
1o The present invention relates to novel compositions and method of applying
these compositions, which comprise of a selected mixture of herbal extracts
and coal
tar, which have the ability to reduce inflammation associated with psoriasis
thereby
encouraging healthy skin growth. The topical application of these novel
compositions
acts to treat skin, which has psoriasis. Topical application means the
introduction of
the novel compositions to the skin via a suitable base or vehicle.
Conventional
understanding of topical applications include but are not limited to creams,
ointments,
lotions, gels, pastes, powders, sprays, washes and the like.
The first novel composition of the present invention is comprised of the
2o following essential herbal extracts and coal tar which have been formulated
into a
body wash composition, which has demonstrated in a reduction of inflammation
associated with skin having psoriasis. Each of the components herein described
is
believed to contribute to the natural healing process of the psoriasis
afflicted area
although the exact mechanisms are not completely understood. The essential
components of the novel body wash composition are: coal tar solution, mallow
extract, rosemary oil, eucalyptus oil, a blend of proteins and wheat germ oil.
The
essential components are included in a suitable carrier for a body wash. More
particularly a preferred composition of the body wash can contain a mixture of
components that act as a carrier, the herbal extracts and coal tar in the
following
proportions given in weight percents as indicated in Table 1.

CA 02305062 2000-04-12
-S-
Psoriasis Body Wash
Substance Percentage RangeFunction
Water 40.19 - 49.12 Inert ingredient
Sodium Laureth Sulfate31.5 - 38.5 Emulsifiers
Cocamide Dea 4.5 - S.5 Thicker and foaming
agent.
Assists in removing
fatty
acids
Cocamidopropyl Betaine0.9 - 1.1 Surfactant used as
a
cleanser.
Propylene Glycol 0.27 - 0.33 Cleanser
Citric Acid 0.27 - 0.33 PH Adjuster
Coal Tar Topical Solution5.4 - 6.6 Active
Sodium Chloride 1.8 - 2.2 Thicker
Sodium Layroyl Sarcosinate1.8 - 2.2 Cleansing
Wheat Germ Oil 0.45 - 0.55 Active
Blends of Proteins 0.18 - 0.22 Active
Methylchloroisothiazolinone0.045 - 0.055 Preservative
Mallow Extract 0.9 - 1.1 Active
Rosemary Oil 0.45 - 0.55 Active
Eucalyptus Oil 0.45 - 0.55 Active/Counterirritant
Carbomer 0.9 - l .l Gelling Agent
It will be apparent from the foregoing that the total percentage weight adds
up
to 100% and therefore the water component of the Psoriasis Body Wash will make
up
the remaining percentage after adding up the percentages of the remaining
components.
Coal tar preparations have been approved for treating psoriasis and other skin
1 o problems such as dandruff. Coal tar is a byproduct of treated bituminous
coal.
Although long term exposure (20-25 years) to high concentrations of coal tar
has been
associated with skin cancer, topical compositions that are not used for long
periods of

CA 02305062 2000-04-12
-6-
time are considered fairly safe as the products are in contact with the skin
for short
periods of time.
Eucalyptus has antiseptic, cooling and stimulating properties. Rosemary is
very rich in natural mineral and has soothing, cleansing, stimulating and
astringent
properties. Mallow has stimulating soothing properties associated with
inflammation.
A second novel composition of the present invention is comprised of the
following essential herbal extracts alone which have been formulated into a
body
to spray composition, which has demonstrated in a reduction of inflammation
associated
with skin having psoriasis. Each of the components herein described is
believed to
contribute to the natural healing process of the psoriasis afflicted area
although the
exact mechanisms are not completely understood. The essential components of
the
novel body spray composition are: mallow extract, rosemary oil, and eucalyptus
oil.
More particularly a preferred composition of the body spray can contain a
mixture of
components that act as the carrier, herbal extracts in the following
proportions given
in weight percents as indicated in Table 2.
Psoriasis Spray
Substance Percentage Range Function
Water 21.573 - 26.367 Inert
Alcohol. 63 - 77 Inert
Sodium Iodide 2.7 - 3.3 Carrier
Potassium Iodide 1.35 - 1.65 Carrier
Sodium Thiosulphate0.027 - 0.033 Neutralizer
Mallow Solution 0.9 - 1.1 Active
Rosemary Solution 0.225 - 0.27 Active
Eucalyptus Oil 0.225 - 0.27 Active
A third novel composition of the present invention is comprised of the
following essential herbal extracts and coal tar which have been formulated
into a

CA 02305062 2000-04-12
cream composition, which has demonstrated in a reduction of inflammation
associated with skin having psoriasis. Each of the components herein described
is
believed to contribute to the natural healing process of the psoriasis
afflicted area
although the exact mechanisms are not completely understood. The essential
components of the novel cream composition are: coal tar solution, mallow
extract,
chamomile extract, and tea tree solution. More particularly a preferred
composition
of the body cream can contain a mixture of components that act as a carrier,
herbal
extracts and coal tar solution in the following proportions given in weight
percents as
indicated in Table 3.
1o Psoriasis Cream
Substance Percentage Range Function
Water 47.0205 - 57.4695 Inert ingredient
Propylene Glycol 3.6 - 4.4 Cleanser
Mineral Oil 2.7 - 3.3 Oil Base
Cetyl Alcohol 3.6 - 4.4 Emulsifier
Stearic Acid 3.6 - 4.4 Emulsifier
Glycerol Monostearate 2.7 - 3.3 Emulsifier
F D & C Yellow #5 Solution0.045 - 0.055 Colour
D & C Red #33 Solution 0.0045 - 0.055 Colour
Chamomile Extract 0.9 - 1.1 Active - Mineral
Carbomer 3.6 - 4.4 Gelling Agent
Methyl Paraben 0.225 - 0.275 Preservative
Propyl Paraben 0.09 - 0.11 Preservative
TriethanolamW a 0.54 - 0.66 Emulsifier
Milk Amino Acids 2.25 - 2.75 Active
Tea Tree Solution 2.7 - 3.3 Active
Mallow Solution 0.9 - 1.1 Active
Coal Tar 5.175 - 6.325 Active
Dimethicone 0.45 - 0.55 Luster Agent
Glycerine 2.7 - 3.3 Humectant
Petrolatum 0.9 - 1.1 Emollient
Cetearyl Alcohol 2.25 - 2.75 Emollient/Thicker
Ceteareth 20 2.25 - 2.75 Lubricant
Polysorbate 20 1.8 - 2.2 Emulsifier

CA 02305062 2000-04-12
_g_
The novel compositions may be used together as a system for use in a
psoriasis treatment. More specifically, in operation, the user may apply the
body
wash composition to the area of skin that is affected with psoriasis. The body
wash
composition may be gently massaged into the affected area then rinsed with
warm
water and dried thoroughly. The novel body spray composition may be applied to
the
affected area and allowed to dry. Once the body spray has dried, the novel
body
cream may be applied to the affected area by massaging the body cream into the
area.
The system may be used on the affected area two to three times a day.
to
The novel compositions may each be used separately or in combination as a
method of treating psoriasis comprising of topically administering to a human
having
psoriasis the novel body wash composition, the body spray composition or the
body
cream composition or a combination of the novel compositions.
The following Examples further illustrate various aspects of the invention.
Example 1
2o In one particular example favourable results were observed by utilizing a
Psoriasis Body Wash, Psoriasis Spray and Psoriasis Cream bearing the following
specific percentage by weight (the specific numerical percentages relate to
the
specific components described earlier, for example, the second item 35.00
under Body
Wash relates to 35% by volume of Sodium Laureth Sulfate, while the second item
under Body Spray relates to 70% by weight alcohol and the second item under
Body
Cream relates to 4% by weight propylene glycol and so on) namely:

CA 02305062 2000-04-12
-9-
Body Wash Body Spray Body Cream
44.65 23.97 52.245
3 5.00 70.00 4.00
5.00 3.00 3.00
1.00 1.50 4.00
0.30 0.03 4.00
0.30 1.00 3.00
6.00 0.25 0.05
2.00 0.25 0.005
2.00 1.00
0.05 4.00
0.20 0.25
0.05 0.10
1.00 0.60
0.5 2.50
0.5 3.00
1.00 1.00
5.75
0.50
3.00
1.00
2.50
2.50
2.00
More particularly, by following the steps of:
(a) apply the body wash composition to the area of skin effected with
psoriasis and gently massaging same to the effected area for a time
period of up to ten minutes and then rinsing same with warm water and
then drying same thereof;

CA 02305062 2000-04-12
-10-
(b) then apply the body spray of the specific composition referred to above
to the effected area, and allowing same to dry;
(c) then apply the body cream having the specific composition referred to
above; and
(d) repeating the steps two to three times a day.
By following the procedure referred to above, on observed a marked
improvement over a span of one month where the area of skin showed a 50%
reduction of psoriasis.
to
Example 2
A 45 year old female patient with long standing psoriasis commenced treating
her psoriasis by first applying the bodywash composition to the area of skin
affected
by psoriasis. The bodywash composition was gently massaged into the affected
area
and then rinsed with warm water and dried thoroughly. The body spray
composition
was sprayed over the affected area and allowed to dry. Finally, the body cream
was
massaged into the affected area. The patient repeated this procedure in the
morning
and the evening over a period of 3 - 4 weeks. The patient's psoriasis cleared
up
2o almost completely, at the end of the 4 week period, with only small amounts
of
psoriasis periodically exhibiting on the patient's skin.
In summary, novel compositions for use in the treatment of psoriasis and
corresponding system and method are provided for wherein the active agents are
coal
tar and a combination of herbal extracts including mallow.
Other variations and modifications of the invention are possible. All such
modifications or variations are believed to be within the sphere and scope of
the
invention as defined by the claims appended hereto.

Representative Drawing

Sorry, the representative drawing for patent document number 2305062 was not found.

Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Application Not Reinstated by Deadline 2012-04-12
Time Limit for Reversal Expired 2012-04-12
Inactive: IPC deactivated 2011-07-29
Inactive: Abandoned - No reply to s.30(2) Rules requisition 2011-05-19
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2011-04-12
Inactive: S.30(2) Rules - Examiner requisition 2010-11-19
Amendment Received - Voluntary Amendment 2010-06-01
Inactive: S.30(2) Rules - Examiner requisition 2009-12-01
Withdraw from Allowance 2009-11-27
Inactive: Adhoc Request Documented 2009-11-27
Inactive: Approved for allowance (AFA) 2009-11-27
Amendment Received - Voluntary Amendment 2008-01-11
Inactive: S.30(2) Rules - Examiner requisition 2007-07-12
Amendment Received - Voluntary Amendment 2007-03-29
Inactive: S.30(2) Rules - Examiner requisition 2007-03-21
Amendment Received - Voluntary Amendment 2007-01-22
Inactive: S.30(2) Rules - Examiner requisition 2006-07-20
Inactive: IPC from MCD 2006-03-12
Inactive: IPC from MCD 2006-03-12
Inactive: IPC from MCD 2006-03-12
Inactive: IPC assigned 2006-02-10
Inactive: IPC assigned 2006-02-10
Inactive: First IPC assigned 2006-02-10
Inactive: Office letter 2003-05-14
Change of Address Requirements Determined Compliant 2003-05-14
Inactive: Office letter 2003-05-13
Inactive: Delete abandonment 2003-05-13
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2003-04-14
Letter Sent 2002-09-05
Revocation of Agent Request 2002-09-04
Appointment of Agent Request 2002-09-04
Amendment Received - Voluntary Amendment 2002-06-28
Request for Examination Requirements Determined Compliant 2002-06-28
All Requirements for Examination Determined Compliant 2002-06-28
Request for Examination Received 2002-06-28
Application Published (Open to Public Inspection) 2001-10-12
Inactive: Cover page published 2001-10-11
Inactive: IPC assigned 2000-06-05
Inactive: IPC assigned 2000-06-05
Inactive: First IPC assigned 2000-06-05
Application Received - Regular National 2000-05-18
Inactive: Filing certificate - No RFE (English) 2000-05-18
Inactive: Applicant deleted 2000-05-18
Small Entity Declaration Determined Compliant 2000-04-12

Abandonment History

Abandonment Date Reason Reinstatement Date
2011-04-12
2003-04-14

Maintenance Fee

The last payment was received on 2010-04-12

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year.
Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Application fee - small 2000-04-12
MF (application, 2nd anniv.) - small 02 2002-04-12 2002-03-22
Request for examination - standard 2002-06-28
MF (application, 3rd anniv.) - small 03 2003-04-14 2003-04-08
MF (application, 4th anniv.) - small 04 2004-04-13 2004-04-07
MF (application, 5th anniv.) - small 05 2005-04-12 2005-04-04
MF (application, 6th anniv.) - small 06 2006-04-12 2006-04-11
MF (application, 7th anniv.) - small 07 2007-04-12 2007-04-12
MF (application, 8th anniv.) - small 08 2008-04-14 2008-04-11
MF (application, 9th anniv.) - small 09 2009-04-14 2009-04-14
MF (application, 10th anniv.) - small 10 2010-04-12 2010-04-12
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
MARIANA DE OLIVEIRA
Past Owners on Record
None
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column. To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Description 2002-06-27 10 475
Claims 2002-06-27 11 389
Abstract 2000-04-11 1 8
Description 2000-04-11 10 410
Claims 2000-04-11 11 318
Claims 2007-01-21 9 248
Claims 2007-03-28 11 245
Claims 2008-01-10 12 306
Claims 2010-05-31 11 284
Filing Certificate (English) 2000-05-17 1 163
Reminder of maintenance fee due 2001-12-12 1 112
Acknowledgement of Request for Examination 2002-09-04 1 177
Courtesy - Abandonment Letter (Maintenance Fee) 2011-06-06 1 172
Courtesy - Abandonment Letter (R30(2)) 2011-08-10 1 164
Correspondence 2002-09-03 2 86
Correspondence 2003-05-12 1 12
Correspondence 2003-05-13 1 15
Fees 2003-04-07 1 34
Fees 2002-03-21 1 31
Fees 2004-04-06 1 27
Fees 2005-04-03 1 26
Fees 2006-04-10 1 26
Fees 2007-04-11 1 30
Fees 2008-04-10 1 25
Fees 2009-04-13 1 32
Fees 2010-04-11 1 30